Meiji Seika Pharma Co., Ltd. and the Foundation for Biomedical Research and Innovation at Kobe announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” conducted at the FBRI’s Dept. of Immunology, Institute of Biomedical Research and Innovation.
Meiji Seika Pharma and FBRI are working together to develop the above PD-1 agonist monoclonal antibody as therapeutic candidate for autoimmune diseases.
PD-1 is a molecule expressed on activated lymphocytes and has the function as a suppressor of immune responses. Antibodies that inhibit the function of PD-1 (anti-PD-1 blocking antibodies) can enhance anti-tumor immunity, so that they have been applied to cancer treatment as “immune checkpoint inhibitors.”
Through the above joint research supervised by Program Director Tasuku Honjo, Nobel laureate in 2018, Meiji Seika Pharma and FBRI discovered the conditions necessary for inducing immunosuppression by stimulating the function of PD-1 with antibodies. “Anti-PD-1 agonist antibody” is expected to be applied as a novel therapeutic for inflammatory diseases such as autoimmune diseases caused by excessive immune reactions.
Meiji Seika Pharma and FBRI continue to progress the joint research on “anti-PD-1 agonist antibody” and strive to the early contribution of this antibody as a therapeutic agent for autoimmune diseases.
*: HBI: Honjo Kobe Research Center for Biomedical Innovation
**: DOI: 10.1126/sciimmunol.add4947
View source version on businesswire.com: https://www.businesswire.com/news/home/20230115005001/en/
Meiji Seika Pharma Co., Ltd.:
Public Relations, Corporate Development Dept.
Email: pr-pharma (Please add “@meiji.com” to the end)
Foundation for Biomedical Research and Innovation at Kobe:
Public relations and Strategic planning group
Email: kbic-pr (Please add “@fbri-kobe.org” to the end)
Source: Meiji Seika Pharma Co., Ltd.
View this news release online at:
http://www.businesswire.com/news/home/20230115005001/en